Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
Beghin
L
L
Dept of Atherosclerosis, INSERM U 325, Institut Pasteur de Lille, France.
Capps
N
N
Duhal
N
N
Davies
J
J
Staels
B
B
Luc
G
G
D016632:Apolipoprotein A-I / Q000097:blood*; D016633:Apolipoprotein A-II / Q000097:blood*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058607:Fibric Acids; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged
D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D058607:Fibric Acids; D008075:Lipoproteins, HDL; D002995:Clofibric Acid; C019304:ciprofibrate